Novel therapeutic strategies for multiple myeloma
- 1 August 2015
- journal article
- review article
- Published by Elsevier in Experimental Hematology
- Vol. 43 (8) , 732-741
Abstract
No abstract availableKeywords
Funding Information
- Specialized Programs of Research Excellence (P50100707, PO1-CA078378, RO1 CA050947)
This publication has 154 references indexed in Scilit:
- Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stressCancer Letters, 2013
- MEK inhibitors as a chemotherapeutic intervention in multiple myelomaBlood Cancer Journal, 2013
- Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicingBlood Cancer Journal, 2012
- Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtypeLeukemia, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myelomaLeukemia, 2011
- Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein responseThe EMBO Journal, 2011
- The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma PathogenesisCancer Cell, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription FactorCell, 2001